Cargando…
Evaluation of Rapid Progressors in HIV Infection as an Extreme Phenotype
DESIGN: Rapid CD4 cell loss represents an HIV phenotype used to identify causal variants of accelerated disease progression. The optimal rate and threshold for identifying this extreme phenotype in recently infected individuals is unclear. METHODS: Using a cohort of patients with known dates of HIV-...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
JAIDS Journal of Acquired Immune Deficiency Syndromes
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4134321/ https://www.ncbi.nlm.nih.gov/pubmed/24872130 http://dx.doi.org/10.1097/QAI.0000000000000240 |
_version_ | 1782330866024841216 |
---|---|
author | Olson, Ashley D. Guiguet, Marguerite Zangerle, Robert Gill, John Perez-Hoyos, Santiago Lodi, Sara Ghosn, Jade Dorrucci, Maria Johnson, Anne Sannes, Mette Moreno, Santiago Porter, Kholoud |
author_facet | Olson, Ashley D. Guiguet, Marguerite Zangerle, Robert Gill, John Perez-Hoyos, Santiago Lodi, Sara Ghosn, Jade Dorrucci, Maria Johnson, Anne Sannes, Mette Moreno, Santiago Porter, Kholoud |
author_sort | Olson, Ashley D. |
collection | PubMed |
description | DESIGN: Rapid CD4 cell loss represents an HIV phenotype used to identify causal variants of accelerated disease progression. The optimal rate and threshold for identifying this extreme phenotype in recently infected individuals is unclear. METHODS: Using a cohort of patients with known dates of HIV-1 seroconversion (SC), CASCADE (Concerted Action on SeroConversion on AIDS and Death in Europe), we identified proportions experiencing nadir CD4 cell levels within 1 year of SC, and assessed their mean AIDS-free survival time at 10-year follow-up and hazard of AIDS/death, compared with those whose CD4 remained >500 cells per cubic millimeter. Follow-up was censored at December 31, 1996 to avoid bias due to combination antiretroviral therapy initiation. RESULTS: Of 4876 individuals, 2.8%, 7.3%, and 24.9% experienced ≥1 CD4 <100, 200, and 350 cells per cubic millimeter, respectively, within 1 year of SC. Minimum CD4 levels of 30, 166, 231, and 506 cells per cubic millimeter were experienced during this period by 1%, 5%, 10%, and 50% of individuals, respectively. Mean (95% confidence interval) AIDS-free survival at 10 years follow-up was 2.9 (2.3 to 3.6), 5.5 (5.0 to 6.1), 6.7 (6.5 to 7.0), 7.4 (7.2 to 7.6), and 8.1 (7.9 to 8.3), for those with minimum counts ≤100, 100–200, 200–350, 350–500, >500 cells per cubic millimeter, respectively. Using counts of >500 cells per cubic millimeter as reference, the hazard ratios (95% confidence interval) of AIDS/death were 15.0 (11.9 to 18.9), 3.6 (2.9 to 4.5), 2.1 (1.8 to 2.4), and 1.5 (1.3 to 1.7), respectively. The hazard ratio increased to 37.5 (26.5 to 53.1) when a minimum CD4 count <100 was confirmed within 1 year of SC. CONCLUSION: At least 1 CD4 ≤100 cells per cubic millimeter within the first year of SC identifies a rare group of individuals at high risk of disease progression and could form the basis for defining the rapid progressor phenotype. |
format | Online Article Text |
id | pubmed-4134321 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | JAIDS Journal of Acquired Immune Deficiency Syndromes |
record_format | MEDLINE/PubMed |
spelling | pubmed-41343212014-09-01 Evaluation of Rapid Progressors in HIV Infection as an Extreme Phenotype Olson, Ashley D. Guiguet, Marguerite Zangerle, Robert Gill, John Perez-Hoyos, Santiago Lodi, Sara Ghosn, Jade Dorrucci, Maria Johnson, Anne Sannes, Mette Moreno, Santiago Porter, Kholoud J Acquir Immune Defic Syndr Basic and Translational Science DESIGN: Rapid CD4 cell loss represents an HIV phenotype used to identify causal variants of accelerated disease progression. The optimal rate and threshold for identifying this extreme phenotype in recently infected individuals is unclear. METHODS: Using a cohort of patients with known dates of HIV-1 seroconversion (SC), CASCADE (Concerted Action on SeroConversion on AIDS and Death in Europe), we identified proportions experiencing nadir CD4 cell levels within 1 year of SC, and assessed their mean AIDS-free survival time at 10-year follow-up and hazard of AIDS/death, compared with those whose CD4 remained >500 cells per cubic millimeter. Follow-up was censored at December 31, 1996 to avoid bias due to combination antiretroviral therapy initiation. RESULTS: Of 4876 individuals, 2.8%, 7.3%, and 24.9% experienced ≥1 CD4 <100, 200, and 350 cells per cubic millimeter, respectively, within 1 year of SC. Minimum CD4 levels of 30, 166, 231, and 506 cells per cubic millimeter were experienced during this period by 1%, 5%, 10%, and 50% of individuals, respectively. Mean (95% confidence interval) AIDS-free survival at 10 years follow-up was 2.9 (2.3 to 3.6), 5.5 (5.0 to 6.1), 6.7 (6.5 to 7.0), 7.4 (7.2 to 7.6), and 8.1 (7.9 to 8.3), for those with minimum counts ≤100, 100–200, 200–350, 350–500, >500 cells per cubic millimeter, respectively. Using counts of >500 cells per cubic millimeter as reference, the hazard ratios (95% confidence interval) of AIDS/death were 15.0 (11.9 to 18.9), 3.6 (2.9 to 4.5), 2.1 (1.8 to 2.4), and 1.5 (1.3 to 1.7), respectively. The hazard ratio increased to 37.5 (26.5 to 53.1) when a minimum CD4 count <100 was confirmed within 1 year of SC. CONCLUSION: At least 1 CD4 ≤100 cells per cubic millimeter within the first year of SC identifies a rare group of individuals at high risk of disease progression and could form the basis for defining the rapid progressor phenotype. JAIDS Journal of Acquired Immune Deficiency Syndromes 2014-09-01 2014-08-13 /pmc/articles/PMC4134321/ /pubmed/24872130 http://dx.doi.org/10.1097/QAI.0000000000000240 Text en Copyright © 2014 by Lippincott Williams & Wilkins This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Basic and Translational Science Olson, Ashley D. Guiguet, Marguerite Zangerle, Robert Gill, John Perez-Hoyos, Santiago Lodi, Sara Ghosn, Jade Dorrucci, Maria Johnson, Anne Sannes, Mette Moreno, Santiago Porter, Kholoud Evaluation of Rapid Progressors in HIV Infection as an Extreme Phenotype |
title | Evaluation of Rapid Progressors in HIV Infection as an Extreme Phenotype |
title_full | Evaluation of Rapid Progressors in HIV Infection as an Extreme Phenotype |
title_fullStr | Evaluation of Rapid Progressors in HIV Infection as an Extreme Phenotype |
title_full_unstemmed | Evaluation of Rapid Progressors in HIV Infection as an Extreme Phenotype |
title_short | Evaluation of Rapid Progressors in HIV Infection as an Extreme Phenotype |
title_sort | evaluation of rapid progressors in hiv infection as an extreme phenotype |
topic | Basic and Translational Science |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4134321/ https://www.ncbi.nlm.nih.gov/pubmed/24872130 http://dx.doi.org/10.1097/QAI.0000000000000240 |
work_keys_str_mv | AT olsonashleyd evaluationofrapidprogressorsinhivinfectionasanextremephenotype AT guiguetmarguerite evaluationofrapidprogressorsinhivinfectionasanextremephenotype AT zangerlerobert evaluationofrapidprogressorsinhivinfectionasanextremephenotype AT gilljohn evaluationofrapidprogressorsinhivinfectionasanextremephenotype AT perezhoyossantiago evaluationofrapidprogressorsinhivinfectionasanextremephenotype AT lodisara evaluationofrapidprogressorsinhivinfectionasanextremephenotype AT ghosnjade evaluationofrapidprogressorsinhivinfectionasanextremephenotype AT dorruccimaria evaluationofrapidprogressorsinhivinfectionasanextremephenotype AT johnsonanne evaluationofrapidprogressorsinhivinfectionasanextremephenotype AT sannesmette evaluationofrapidprogressorsinhivinfectionasanextremephenotype AT morenosantiago evaluationofrapidprogressorsinhivinfectionasanextremephenotype AT porterkholoud evaluationofrapidprogressorsinhivinfectionasanextremephenotype |